vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $183.1M, roughly 1.1× Amphastar Pharmaceuticals, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -1.8%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $24.6M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
AMPH vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $196.9M |
| Net Profit | $24.4M | — |
| Gross Margin | 46.8% | 79.5% |
| Operating Margin | 19.4% | 1.2% |
| Net Margin | 13.3% | — |
| Revenue YoY | -1.8% | 5.1% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $196.9M | ||
| Q3 25 | $191.8M | $179.5M | ||
| Q2 25 | $174.4M | $181.1M | ||
| Q1 25 | $170.5M | $168.9M | ||
| Q4 24 | $186.5M | $187.3M | ||
| Q3 24 | $191.2M | $168.6M | ||
| Q2 24 | $182.4M | $178.0M | ||
| Q1 24 | $171.8M | $167.1M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $5.4M | ||
| Q2 25 | $31.0M | $-4.8M | ||
| Q1 25 | $25.3M | $4.8M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-143.5M | ||
| Q2 24 | $37.9M | $18.9M | ||
| Q1 24 | $43.2M | $9.0M |
| Q4 25 | 46.8% | 79.5% | ||
| Q3 25 | 51.4% | 80.9% | ||
| Q2 25 | 49.6% | 77.4% | ||
| Q1 25 | 50.0% | 79.7% | ||
| Q4 24 | 46.5% | 78.7% | ||
| Q3 24 | 53.3% | 76.9% | ||
| Q2 24 | 52.2% | 75.1% | ||
| Q1 24 | 52.4% | 71.6% |
| Q4 25 | 19.4% | 1.2% | ||
| Q3 25 | 13.2% | 3.5% | ||
| Q2 25 | 24.2% | 4.7% | ||
| Q1 25 | 21.9% | 1.2% | ||
| Q4 24 | 24.2% | 13.2% | ||
| Q3 24 | 29.8% | -82.8% | ||
| Q2 24 | 30.3% | 15.9% | ||
| Q1 24 | 27.9% | 7.9% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 3.0% | ||
| Q2 25 | 17.8% | -2.7% | ||
| Q1 25 | 14.8% | 2.8% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -85.1% | ||
| Q2 24 | 20.8% | 10.6% | ||
| Q1 24 | 25.1% | 5.4% |
| Q4 25 | $0.51 | $0.05 | ||
| Q3 25 | $0.37 | $0.12 | ||
| Q2 25 | $0.64 | $-0.11 | ||
| Q1 25 | $0.51 | $0.10 | ||
| Q4 24 | $0.74 | $0.38 | ||
| Q3 24 | $0.78 | $-3.11 | ||
| Q2 24 | $0.73 | $0.39 | ||
| Q1 24 | $0.81 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $238.4M |
| Total DebtLower is stronger | $608.7M | $372.2M |
| Stockholders' EquityBook value | $788.8M | $693.1M |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | 0.77× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $238.4M | ||
| Q3 25 | $276.2M | $246.3M | ||
| Q2 25 | $231.8M | $445.9M | ||
| Q1 25 | $236.9M | $493.6M | ||
| Q4 24 | $221.6M | $484.6M | ||
| Q3 24 | $250.5M | $453.8M | ||
| Q2 24 | $217.8M | $404.2M | ||
| Q1 24 | $289.6M | $325.9M |
| Q4 25 | $608.7M | $372.2M | ||
| Q3 25 | $608.6M | $376.7M | ||
| Q2 25 | $607.7M | $580.5M | ||
| Q1 25 | $603.9M | $583.4M | ||
| Q4 24 | $601.6M | $585.3M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $693.1M | ||
| Q3 25 | $776.7M | $727.2M | ||
| Q2 25 | $757.5M | $757.8M | ||
| Q1 25 | $751.3M | $798.5M | ||
| Q4 24 | $732.3M | $778.3M | ||
| Q3 24 | $727.7M | $749.6M | ||
| Q2 24 | $713.3M | $879.3M | ||
| Q1 24 | $672.4M | $892.2M |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.6B | $1.6B |
| Q4 25 | 0.77× | 0.54× | ||
| Q3 25 | 0.78× | 0.52× | ||
| Q2 25 | 0.80× | 0.77× | ||
| Q1 25 | 0.80× | 0.73× | ||
| Q4 24 | 0.82× | 0.75× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $43.7M |
| Free Cash FlowOCF − Capex | $24.6M | $43.5M |
| FCF MarginFCF / Revenue | 13.4% | 22.1% |
| Capex IntensityCapex / Revenue | 4.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $43.7M | ||
| Q3 25 | $52.6M | $60.8M | ||
| Q2 25 | $35.6M | $12.0M | ||
| Q1 25 | $35.1M | $35.5M | ||
| Q4 24 | $29.0M | $33.1M | ||
| Q3 24 | $60.0M | $53.9M | ||
| Q2 24 | $69.1M | $53.2M | ||
| Q1 24 | $55.3M | $49.1M |
| Q4 25 | $24.6M | $43.5M | ||
| Q3 25 | $47.2M | $57.0M | ||
| Q2 25 | $25.0M | $9.3M | ||
| Q1 25 | $24.4M | $26.9M | ||
| Q4 24 | $16.6M | $31.0M | ||
| Q3 24 | $46.2M | $49.8M | ||
| Q2 24 | $63.1M | $51.6M | ||
| Q1 24 | $46.5M | $46.3M |
| Q4 25 | 13.4% | 22.1% | ||
| Q3 25 | 24.6% | 31.7% | ||
| Q2 25 | 14.3% | 5.1% | ||
| Q1 25 | 14.3% | 15.9% | ||
| Q4 24 | 8.9% | 16.6% | ||
| Q3 24 | 24.1% | 29.6% | ||
| Q2 24 | 34.6% | 29.0% | ||
| Q1 24 | 27.1% | 27.7% |
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 2.2% | ||
| Q2 25 | 6.1% | 1.5% | ||
| Q1 25 | 6.3% | 5.1% | ||
| Q4 24 | 6.7% | 1.1% | ||
| Q3 24 | 7.2% | 2.4% | ||
| Q2 24 | 3.3% | 0.9% | ||
| Q1 24 | 5.1% | 1.7% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 11.20× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 7.37× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 2.82× | ||
| Q1 24 | 1.28× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
